Hepatitis E, caused by infection with waterborne hepatitis E virus (HEV) is endemic in several developing countries, particularly in Asia and Africa. In the Indian subcontinent, hepatitis E occurs as large outbreaks. Whereas the disease is usually self-limiting, about 1% of patients develop fulminant hepatic failure (FHF), a syndrome with 50-80% mortality. The disease is especially severe among pregnant women, who develop FHF more often and have mortality rates as high as 20-30% following infection with HEV. A prophylactic vaccine is being developed against this infection, no specific therapy is however yet available. To develop the latter, a better understanding of the mechanism of liver injury in HEV infection, whether the virus itself or the host's immune response, is needed. The lack of an in vitro culture system and a small animal model makes it difficult to determine whether the virus is cytopathic. The limited cellular immune response data currently available are based on studies of peripheral blood mononuclear cells and may not accurately reflect the immune events in the liver, the major site of injury. Also, no prognostic marker has yet been developed to help identify those patients with hepatitis E who are at risk for developing FHF. Our hypothesis is that the liver injury and severity of disease in hepatitis E are determined primarily by the host response to viral infection. This proposal, therefore, aims to (a) characterize the immune events in the liver tissue of patients with acute hepatitis E (number of CD4+ T cells, CD8+ T cells and NK cell, and their localization in relation to HEV antigen - using immunofluorescence and confocal microscopy), (b) characterize the expression of host genes in the liver, the primary target organ for infection (using microarray techniques), and (c) discovery of protein biomarkers in the plasma or urine for differentiation between acute self-limited and fulminant hepatitis E (using proteomic techniques), and validation in a separate group of patients. The information obtained from the proposed work will help advance our understanding of the mechanisms of liver injury in hepatitis E, will provide useful biomarkers to guide the clinical care of patients with this disease and may help identify potential targets for therapeutic intervention in patients with severe forms of this disease. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI076192-01
Application #
7324368
Study Section
Special Emphasis Panel (ZAI1-GSM-M (M1))
Program Officer
Koshy, Rajen
Project Start
2007-09-01
Project End
2011-08-31
Budget Start
2007-09-01
Budget End
2008-08-31
Support Year
1
Fiscal Year
2007
Total Cost
$78,840
Indirect Cost
Name
International Center/Genetic/Eng/Biotech
Department
Type
DUNS #
915825318
City
New Delhi
State
Country
India
Zip Code
11006-7
Naik, Anshu; Goel, Amit; Agrawal, Vinita et al. (2015) Changes in gene expression in liver tissue from patients with fulminant hepatitis E. World J Gastroenterol 21:8032-42
Chandra, Vivek; Holla, Prasida; Ghosh, Dhrubaa et al. (2011) The hepatitis E virus ORF3 protein regulates the expression of liver-specific genes by modulating localization of hepatocyte nuclear factor 4. PLoS One 6:e22412
Ippagunta, S K; Naik, S; Jameel, S et al. (2011) Viral RNA but no evidence of replication can be detected in the peripheral blood mononuclear cells of hepatitis E virus-infected patients. J Viral Hepat 18:668-72
Munshi, S U; Taneja, S; Bhavesh, N S et al. (2011) Metabonomic analysis of hepatitis E patients shows deregulated metabolic cycles and abnormalities in amino acid metabolism. J Viral Hepat 18:e591-602
Ahmad, Imran; Holla, R Prasida; Jameel, Shahid (2011) Molecular virology of hepatitis E virus. Virus Res 161:47-58
Taneja, Shikha; Sen, Somdutta; Gupta, Vijay K et al. (2009) Plasma and urine biomarkers in acute viral hepatitis E. Proteome Sci 7:39